Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
Date:8/11/2008

CAMBRIDGE, Mass., Aug. 11 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. today announced that the first patient has received an initial dose in a Phase 1 clinical study of the Company's first oncology product, MM-121, a fully human monoclonal antibody and a first-in-class therapeutic designed to block signaling of the ErbB3 receptor.

ErbB3 is a receptor in the ErbB family, a pathway that plays a critical role in cancer signaling. With the initiation of the Phase 1 trial, MM-121 becomes the first systems biology product as well as the first selective ErbB3 antagonist to enter human clinical development.

"We used a combination of high-throughput biology and computer simulation to discern the importance of targeting ErbB3 signaling in tumor cells," said Dr. Ulrik B. Nielsen, Senior Vice President of Research. "We believe this is the first systems-designed therapeutic in clinical development. Until now, computer simulation has not been widely applied toward understanding optimal therapeutic strategies for treating cancers driven by complex signaling pathways."

Preclinical data demonstrating the impact of MM-121 in multiple cancer models were presented at the annual meeting of the American Association for Cancer Research in April. The Phase 1 dose escalation study will evaluate the safety and pharmacokinetics (PK) of MM-121. Enrollment is underway at Fox Chase Cancer Center and two additional leading oncology sites are expected to participate in the trial later this year.

"ErbB3 is now recognized as a potentially important target in many types of cancer including lung, breast, colorectal, ovarian and others," said Dr. William J. Slichenmyer, Senior Vice President and Chief Medical Officer at Merrimack. "Preclinical studies of MM-121 have demonstrated antitumor activity in a wide range of tumor types and a very favorable safety profile. We are optimistic that these findings may translate into clinical benefit for patients who participat
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
2. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... 27, 2014 First articles ... Elsevier , a world-leading provider of ... pleased to announce the launch of a new journal: ... The launch of Extreme Mechanics Letters ... the forefront of applied sciences such as micro and ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 2014 ... is a professional and in-depth research report on ... information, like its definition, classification, application, and industry ... report covers the international market analysis, including China’s ... the US, Europe, Asia, China, Japan etc. regions) ...
(Date:11/26/2014)... , Nov. 26, 2014 The ... from a survey of European physicians at the ... Innovation and Biological Therapies" at the Spanish Ministry ... hosted by EuropaBio and the Spanish Bioindustry Association ... Health, physicians from Spanish oncology and rheumatology societies, ...
(Date:11/26/2014)... 2014 SonaCare Medical, a leading ... devices, recently participated in the American Urology Association’s ... .” Key opinion leaders in urology presented on ... small renal masses while attendees had the opportunity ... in hands-on labs. Attendees at the Los Angeles, ...
Breaking Biology Technology:Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3ASBM Presents European Physicians Survey at Spanish Ministry of Health 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3
... 2 NicOx S.A.,(NYSE Euronext Paris: COX) ... with,DSM for the commercial manufacture and supply ... ingredient). Naproxcinod is NicOx, lead,investigational product and ... (CINOD) class of,anti-inflammatory agents, which recently achieved ...
... Inc., announced today the appointment of Ellen McDonald to ... Business Operations and Chief Business Officer, effective immediately. ... experience in the biopharmaceutical industry, with expertise heading business ... report to David J. Mazzo, Ph.D., the Company,s President ...
... Sheets: CGCP), a leading developer of surgical products used in ... the addition of veteran medical device executive and an experienced ... the Company,s Board of Directors, increasing the number of board ... Mr. Cohen, 49, has over 25 years of executive experience ...
Cached Biology Technology:NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer 2Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 2Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors 3
(Date:11/6/2014)... Medicine, Inc, a Baltimore-based bioinformatics company focused on ... a research collaboration with the international leader in ... CSBR). , "There are many companies utilizing advances ... TumorGraft technology is unique in a way that ... vast amounts of valuable data. Our bioinformatic analysis ...
(Date:11/5/2014)... has dedicated his career to understanding the Earth,s ... audience. , As deputy director and regional climatologist ... Desert Research Institute, Redmond has more than three ... dissemination of climate data to the general public. ... San Francisco on December 15-19, 2014 the American ...
(Date:11/4/2014)... University of Utah engineers developed the first room-temperature fuel ... electricity without needing to ignite the fuel. These new ... off-grid power and sensors. , A study of the ... Society journal ACS Catalysis . , Fuel cells ... a fuel and an oxygen-rich source such as air. ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Jet-fueled electricity at room temperature 2
... help may be on the way. That,s because scientists ... promotes new bone growth. This opens the door to ... they are getting a workout. The research report describing ... Journal ( http://www.fasebj.org ). This research provides ...
... prevalent diabetes-induced complications in men; current estimates suggest that as ... degree of ED, and in many cases diabetics develop more ... drugs. Now, in a study appearing in the March ... Reserve University and Albert Einstein College of Medicine have identified ...
... radiated only 70 to 75 percent as much energy as it ... energy reaching the planet,s surface, all water on the planet should ... early Earth was awash in liquid water a planetary ocean ... output and kept Earth,s water wet. To explain this apparent ...
Cached Biology News:For osteoporosis patients, exercise pill one step closer to reality 2Early Earth absorbed more sunlight -- no extreme greenhouse needed to keep water wet 2Early Earth absorbed more sunlight -- no extreme greenhouse needed to keep water wet 3Early Earth absorbed more sunlight -- no extreme greenhouse needed to keep water wet 4
Mouse monoclonal antibody raised against a partial recombinant PUM2. NCBI Entrez Gene ID = PUM2...
...
Mouse monoclonal antibody raised against a partial recombinant AATK. NCBI Entrez Gene ID = AATK...
... The Rotofor purification system with PowerPac 3000 ... protein separation and purification by liquid-phase isoelectric ... mini (18 ml) and standard (60 ml) ... electrode chambers, PowerPac 3000 power supply, 10 ...
Biology Products: